Azitra, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZTR research report →
Companyazitrainc.com
Azitra, Inc. , a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S.
- CEO
- Francisco D. Salva
- IPO
- 2023
- Employees
- 12
- HQ
- Branford, CT, US
Price Chart
Valuation
- Market Cap
- $2.12M
- P/E
- -0.26
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 882.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.45%
- ROIC
- -0.11%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-10,955,370 · -22.17%
- EPS
- $-2.25 · -532.28%
- Op Income
- $-10,966,665
- FCF YoY
- -8.02%
Performance & Tape
- 52W High
- $2.40
- 52W Low
- $0.10
- 50D MA
- $0.22
- 200D MA
- $0.44
- Beta
- -1.39
- Avg Volume
- 12.10M
Get TickerSpark's AI analysis on AZTR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Staskey Norm | other | 35,524 |
| Apr 20, 26 | Salva Francisco D. | other | 220,879 |
| Apr 20, 26 | Whitfill Travis | other | 64,300 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 500 |
| Dec 19, 25 | Whitfill Travis | other | 23,724 |
| Dec 19, 25 | Salva Francisco D. | other | 59,309 |
| Dec 19, 25 | Ryan Barbara | other | 3,003 |
| Dec 19, 25 | Staskey Norm | other | 15,015 |
Our AZTR Coverage
We haven't published any research on AZTR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AZTR Report →